Last updated: 21 June 2024 at 4:18pm EST

Avraham Gabay Net Worth



Avraham Gabay biography

Avraham Gabay CPA serves as Chief Financial Officer, Treasurer, Secretary of the Company. Prior to his appointment, from March 2015 until May 2019, Mr. Gabay served as a corporate controller at Orcam Technologies Ltd., a company which develops, manufactures and sells a wearable assistive technology device for people who are blind, visually impaired or have reading or other disabilities. From 2014 to 2015, Mr. Gabay provided economic services in the advisory department of KPMG Israel, a certified public accounting firm. From 2013 until 2014, Mr. Gabay worked in the tax department of the law firm, Gornitzky & Co. Mr. Gabay holds a bachelor’s degree in law and accounting from Tel-Aviv University and is a certified public accountant in Israel and a member of the Israeli Bar Association.s

What is the salary of Avraham Gabay?

As the Chief Financial Officer、 Treasurer、 Secretary of Oramed Pharmaceuticals, Inc, the total compensation of Avraham Gabay at Oramed Pharmaceuticals, Inc is 115,491$. There are 9 executives at Oramed Pharmaceuticals, Inc getting paid more, with Nadav Kidron having the highest compensation of 1,551,100$.



How old is Avraham Gabay?

Avraham Gabay is 35, he's been the Chief Financial Officer、 Treasurer、 Secretary of Oramed Pharmaceuticals, Inc since 2019. There are 14 older and no younger executives at Oramed Pharmaceuticals, Inc. The oldest executive at Oramed Pharmaceuticals, Inc is Dr. Miriam Kidron Ph.D., 81, who is the Chief Scientific Officer & Director.

What's Avraham Gabay's mailing address?

Avraham's mailing address filed with the SEC is 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, , NEW YORK, NY, 10036.

Insiders trading at Oramed Pharmaceuticals, Inc

Over the last 17 years, insiders at Oramed Pharmaceuticals, Inc have traded over 7,377,390$ worth of Oramed Pharmaceuticals, Inc stock and bought 881,642 units worth 3,583,418$ . The most active insiders traders include Miriam KidronLeonard SankNadav Kidron. On average, Oramed Pharmaceuticals, Inc executives and independent directors trade stock every 111 days with the average trade being worth of 97,149$. The most recent stock trade was executed by Arie Mayer on 3 April 2023, trading 8,809 units of ORMP stock currently worth 19,556$.



What does Oramed Pharmaceuticals, Inc do?

oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg



What does Oramed Pharmaceuticals, Inc's logo look like?

Oramed Pharmaceuticals, Inc logo

Oramed Pharmaceuticals, Inc executives and stock owners

Oramed Pharmaceuticals, Inc executives and other stock owners filed with the SEC include: